Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: kalarx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2022 | Neutral → Underweight | JP Morgan | |
| 8/6/2021 | $14.00 → $11.00 | Buy | HC Wainwright & Co. |
| 8/6/2021 | Overweight → Neutral | JP Morgan |
10-Q - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
424B5 - KALA BIO, Inc. (0001479419) (Filer)
10-Q - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
EFFECT - KALA BIO, Inc. (0001479419) (Filer)
424B3 - KALA BIO, Inc. (0001479419) (Filer)
S-3 - KALA BIO, Inc. (0001479419) (Filer)
D - KALA BIO, Inc. (0001479419) (Filer)
8-K - KALA BIO, Inc. (0001479419) (Filer)
3 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
4 - KALA BIO, Inc. (0001479419) (Issuer)
SC 13G - KALA BIO, Inc. (0001479419) (Subject)
SC 13D - KALA BIO, Inc. (0001479419) (Subject)
SC 13D - KALA BIO, Inc. (0001479419) (Subject)
SC 13G - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13D/A - KALA BIO, Inc. (0001479419) (Subject)
SC 13G - Kala Pharmaceuticals, Inc. (0001479419) (Subject)
SC 13G - Kala Pharmaceuticals, Inc. (0001479419) (Subject)
JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight
HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously
JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral
HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $16.00 previously
HC Wainwright resumed coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $17.00
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "We continue to advance our proprietary mesenchymal stem cell secretome (MSC-S) platform a
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors. Dr. Farid, who is currently Professor of Clinical Ophthalmology, Director of Cornea, Refractive & Cataract Surgery, and Vice Chair of Ophthalmic Faculty at the Gavin Herbert Eye Institute, University of California Irvine (UCI), founded the Severe Ocular Surface Disease Center at UCI and is an industry leader in the care and treatment of
WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers to its Board of Directors. Mr. Myers, who has more than 35 years of ophthalmic pharmaceutical experience, will serve as a Class III director, and join both the Compensation and Nominating and Corporate Governance Committees. "We are very pleased to welcome Dan to our Board of Directors," said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. "Dan has an
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the CHASE trial in Argentina; additional sites in Latin America in process, subject to regulatory clearance -- ARLINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. "We remain focused on ad
ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the H.C. Wainwright 4th Annual Ophthalmology Conference, which is being held virtually. A pre-recorded presentation will be made available beginning on Thursday, August 15, 2024 at 7:00 a.m. ET. Management will also be available for virtual one-on-one meetings throughout the conference. To access the webcast and subsequent archived rec
-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million as of June 30, 2024, together with anticipated funding remaining from CIRM award, expected to fund operations into 4Q 2025 – -- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 -- ARLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for th
ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeemable Preferred Stock (the "Series H Preferred Stock"), for aggregate gross proceeds of approximately $12.5 million, before deducting offering expenses. The private placement was led by SR One wi
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- -- Cash resources of $48.5 million as of March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, toda
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also be available for one-on-one meetings on Monday, March 4, 2024. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA web
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually. A pre-recorded fireside chat will be made available beginning on Tuesday, February 13, 2024 at 12:00 p.m. ET. Management will also be available for one-on-one meetings throughout the conference. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentation
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 3,125 shares of its common stock to one new employee. The stock options were granted on January 16, 2024. The grant was approved by the Compensation Committee and made as a material inducement to such employee entering into employment with KALA in accordance with Nasdaq Listing Rule 5635(c)(4). The option award has
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov
ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se
- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 2022 - - Conference Call and Webcast at 8:00 a.m. ET - ARLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2022 financial results on Monday, May 16, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access this conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 6384677. To access a live webcast and subsequent archived recording of the call, pl
-- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-012 expected in 4Q 2022 ---- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7368936. To access a live webcast and subsequent archived record
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference Call and Webcast at 10:30 a.m. ET -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. "We have made progress toward our goal of providing patients and physicians with a portfolio of i
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial ---- Kala expects to initiate Phase 2/3 trial in 3Q 2022 ----Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kala's Board of Directors ---- Management to host conference call at 10:30 a.m. ET today -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the d
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15th at 10:30 am. ET. The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7298039. To access a live webcast and subse
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $21 to $18.
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.20) per share which missed the analyst consensus estimate of $(2.89) by 45.33 percent.
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $22 to $21.
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.
Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million. Travere Therapeutics (NASDAQ:TVTX) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million. MSP Recovery (NASDAQ:LIFW) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million. Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million. Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion. Kala Bio
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to $22.
Kala Bio (NASDAQ:KALA) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Kala Bio missed estimated earnings by 58.6%, reporting an EPS of $-3.41 versus an estimate of $-2.15. Revenue was down $420 thousand from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $1.17 which was followed by a 1.6% drop in the share price the next day. To track all earnings releases for Kala Bio visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate of $(2.15) by 58.6 percent. This is a 61.77 percent increase over losses of $(8.92) per share from the same period last year.